Retatrutide: The Triple-Agonist Peptide and What Its Published Trial Data Shows

Published July 27, 2026 · Universe Peptide Research Desk

Retatrutide is among the most closely watched investigational peptides in metabolic pharmacology. Unlike single-target incretin analogues, it is one molecule that acts at three receptors at once. Its development program has now produced peer-reviewed Phase 2 results in two major journals and topline Phase 3 results from the sponsor. This article summarises what those published sources actually report.

One peptide, three receptors

Retatrutide is a single synthetic peptide that acts as an agonist at three distinct receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This is the structural feature that distinguishes it from GLP-1 mono-agonists and from GIP/GLP-1 dual agonists.

A note on terminology, since it appears frequently in commercial listings: retatrutide is sometimes marketed under the label "GLP-3." There is no GLP-3 receptor in human physiology. The term is a marketing shorthand, not a scientific one. The accurate description is a triple GIP / GLP-1 / glucagon receptor agonist, and that is how it is described in every peer-reviewed publication on the compound.

Mechanistically, the addition of glucagon-receptor agonism is what makes the molecule scientifically interesting. Glucagon-receptor signalling is associated with increased energy expenditure, whereas GLP-1 and GIP agonism are associated primarily with effects on satiety and insulin secretion. Combining all three in one peptide is a deliberate attempt to engage both sides of the energy balance equation, and it is the central hypothesis the trial program was built to test.

Phase 2: the peer-reviewed record

Two Phase 2 trials were published in 2023 and remain the primary peer-reviewed literature on the compound.

In The Lancet (Rosenstock J, Friás J, Jastreboff AM, et al., 2023;402(10401):529–544), a randomised, double-blind, placebo- and active-controlled Phase 2 trial enrolled 281 participants with type 2 diabetes across eight treatment arms. At 24 weeks the investigators reported dose-dependent reductions in HbA1c ranging from −0.43% at the lowest dose to −2.02% at 12 mg. Reported adverse events were consistent with the incretin class and predominantly mild-to-moderate gastrointestinal effects; the authors recorded no severe hypoglycaemia and no deaths during the study.

A companion Phase 2 obesity trial was published in The New England Journal of Medicine (doi:10.1056/NEJMoa2301972), establishing the dose-response relationship that the Phase 3 program went on to test.

Phase 3: the TRIUMPH program

The Phase 3 program, TRIUMPH, has reported topline results through the sponsor. In TRIUMPH-4 (NCT05931367), a 68-week trial randomising 445 adults with obesity or overweight and knee osteoarthritis, without diabetes, the sponsor reported mean body-weight reductions of 26.4% at 9 mg and 28.7% at 12 mg, against −2.1% for placebo. Co-reported WOMAC pain scores fell by 4.5 and 4.4 points in the two active arms respectively. Notably, 84.0% of enrolled participants had a baseline BMI of 35 kg/m² or above.

These are topline sponsor announcements, not yet the full peer-reviewed publications. That distinction matters when weighing evidence: press-release figures precede the complete dataset, the full safety tables, and independent peer review. The sponsor's own materials state plainly that there is no guarantee retatrutide will receive regulatory approval.

Why the compound draws laboratory interest

From a research standpoint, retatrutide is a useful tool compound precisely because its tri-agonism isolates a question that mono- and dual-agonists cannot: what does adding glucagon-receptor engagement contribute, independent of the incretin arms? That question is studied in receptor-binding assays, cell-based signalling work, and animal models — the settings in which research-grade material is appropriately used. None of that work involves, or licenses, administration to humans.

Regulatory position, stated plainly

Retatrutide holds no marketing authorisation in any jurisdiction. It is not a compoundable substance, not a supplement, and not a prescribable medicine. Any material offered for sale outside a pharmaceutical supply chain is a research chemical and nothing else. Laboratories sourcing it are responsible for handling it under their own institutional and jurisdictional requirements.

Sources

1. Rosenstock J, Friás J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet. 2023;402(10401):529–544. PubMed 37385280
2. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. doi:10.1056/NEJMoa2301972. nejm.org
3. Phase 3 TRIUMPH-4 topline results (NCT05931367). Eli Lilly and Company, investor release. investor.lilly.com

This article is provided for educational and informational purposes to the research community and reports on publicly available scientific and corporate disclosures. Universe Peptide products are sold for laboratory research only, are not for human or animal consumption, and are not approved by the FDA for any therapeutic use. Buyers must be 21+.